Regencell Bioscience Holdings Limited RGC
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -11.70M | -9.38M | -7.05M | -5.32M | -3.58M |
| Total Depreciation and Amortization | 404.60K | 393.20K | 381.80K | 387.30K | 392.80K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 3.20M | 2.92M | 2.65M | 1.35M | 59.00K |
| Change in Net Operating Assets | 398.80K | 208.80K | 18.80K | 18.80K | 18.80K |
| Cash from Operations | -7.70M | -5.85M | -4.00M | -3.56M | -3.11M |
| Capital Expenditure | -- | -76.30K | -152.60K | -152.60K | -152.60K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 2.50M | 3.80M | 5.09M | 3.96M | 2.84M |
| Cash from Investing | 2.50M | 3.72M | 4.93M | 3.81M | 2.69M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 18.72M | 9.36M | -- | -- | -- |
| Repurchase of Common Stock | -1.78M | -889.40K | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 16.95M | 8.47M | -- | -- | -- |
| Foreign Exchange rate Adjustments | 18.80K | -66.80K | -152.40K | -133.50K | -114.60K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 11.77M | 6.28M | 780.80K | 119.30K | -542.20K |